SIGA Technologies is a commercial-stage health security company focused on the treatment of smallpox and other orthopoxvirus. It has contracts with both the US and Canadian governments for TPOXX, its treatment for smallpox, and is expanding internationally.
With c 94,000 global cases and 32,000 cases in the US since 2022, mpox remains a growing concern especially given the rising numbers of clade 1 (severe) cases in Democratic Republic of Congo. TPOXX was approved by the US FDA for smallpox and is now available to treat mpox through the Centers for Disease Control and Prevention’s expanded access investigational new drug protocol. Currently, it is the only allowed therapy for all orthopoxvirus pathogens, including mpox, approved in both the UK and the EU.
Healthcare |
Flash note
Healthcare |
Update
Healthcare |
Flash note
Healthcare |
Update
Daniel Luckshire
Executive VP and CFO
Diem Nguyen
CEO
Forecast net cash (US$m)
166.6
Forecast gearing ratio (%)
N/A
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 6.0 | 93.3 | 60.1 |
Relative | 10.7 | 88.9 | 32.9 |
52 week high/low | US$9.9/US$4.3 |
SIGA Technologies is a commercial-stage company focused on the treatment of smallpox and other orthopoxviruses. Lead drug TPOXX was approved by the US FDA in 2018 for the treatment of smallpox and in the EU and UK under the broad label including all orthopox pathogens in 2022. SIGA reported solid FY23 results, with product revenues growing 50.8% to $130.7m driven by Q423 deliveries to the US SNS and HERA, and management announcing a special cash dividend of $0.6/share. Following an amended contract with Meridian, SIGA will actively manage international promotion activities effective June 2024. We continue to view the PEP label expansion as a key future value driver for SIGA and view the commercial launch of Jynneos vaccine (SIGA peer) as a positive for the company.
Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2022A | 110.8 | 43.2 | 43.7 | 45.56 | 20.4 | 16.3 |
2023A | 139.9 | 84.2 | 87.8 | 94.96 | 9.8 | 7.0 |
2024E | 190.6 | 104.4 | 108.4 | 122.41 | 7.6 | 11.2 |
2025E | 169.3 | 96.3 | 100.7 | 118.95 | 7.8 | 8.8 |